Cargando…

A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer

INTRODUCTION: The aim of the study was to perform a comparative analysis of LOH (loss of heterozygosity) in primary tumors as well as peripheral blood and bone marrow (BM) of patients with breast cancer (BCa). METHODS: Performing PCR-based fluorescence microsatellite analysis and using a panel of se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwarzenbach, Heidi, Müller, Volkmar, Beeger, Cord, Gottberg, Miriam, Stahmann, Nicole, Pantel, Klaus
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242661/ https://www.ncbi.nlm.nih.gov/pubmed/17915011 http://dx.doi.org/10.1186/bcr1772

Ejemplares similares

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2009)

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
por: Eichelser, Corinna, et al.
Publicado: (2014)

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
por: Roth, Carina, et al.
Publicado: (2011)

Interplay of lncRNA H19/miR‐675 and lncRNA NEAT1/miR‐204 in breast cancer
por: Müller, Volkmar, et al.
Publicado: (2019)

Circulating microRNAs: promising breast cancer biomarkers - authors' response
por: Roth, Carina, et al.
Publicado: (2011)

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
por: Roth, Carina, et al.
Publicado: (2010)

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016)

Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives
por: Müller, Volkmar, et al.
Publicado: (2004)

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
por: Ni, Qingtao, et al.
Publicado: (2018)

Exosomal microRNAs as tumor markers in epithelial ovarian cancer
por: Pan, Chi, et al.
Publicado: (2018)

Author Correction: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
por: Ni, Qingtao, et al.
Publicado: (2019)

Circulating DNA as biomarker in breast cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2015)

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
por: Meng, Xiaodan, et al.
Publicado: (2015)

Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by Methyl-CpG binding proteins and histone modifications
por: Müller, Imke, et al.
Publicado: (2010)

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients
por: Stückrath, Isabel, et al.
Publicado: (2015)

Loss of heterozygosity: what is it good for?
por: Ryland, Georgina L., et al.
Publicado: (2015)

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
por: Soloveva, Maiia, et al.
Publicado: (2023)

A new method to detect loss of heterozygosity using cohort heterozygosity comparisons
por: Green, Michael R, et al.
Publicado: (2010)

Loss of Heterozygosity and Its Importance in Evolution
por: Smukowski Heil, Caiti
Publicado: (2023)

Loss of heterozygosity of TRIM3 in malignant gliomas
por: Boulay, Jean-Louis, et al.
Publicado: (2009)

Analysis of Loss of Heterozygosity in Korean Patients with Keratoacanthoma
por: Ha, Tae-Won, et al.
Publicado: (2005)

Loss of Heterozygosity Drives Adaptation in Hybrid Yeast
por: Smukowski Heil, Caiti S., et al.
Publicado: (2017)

Targeting tumor vulnerabilities associated with loss of heterozygosity
por: Rendo, Veronica, et al.
Publicado: (2020)

Fitness benefits of loss of heterozygosity in Saccharomyces hybrids
por: Lancaster, Samuel M., et al.
Publicado: (2019)

Targeting loss of heterozygosity for cancer-specific immunotherapy
por: Hwang, Michael S., et al.
Publicado: (2021)

Polyploidy as an Adaptation against Loss of Heterozygosity in Cancer
por: Archetti, Marco
Publicado: (2022)

Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma
por: Pastorino, Lorenza, et al.
Publicado: (2022)

Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors
por: Roth, Carina, et al.
Publicado: (2012)

Characterization of immunologically detectable T-cell sensitization, Immunohistochemical detection of pro-inflammatory cytokines, and clinical parameters of patients after allogeneic intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans
por: Solakoglu, Önder, et al.
Publicado: (2022)

A loss of heterozygosity, a loss in competition? The effects of inbreeding, pre‐ and postnatal conditions on nestling development
por: de Boer, Raïssa A., et al.
Publicado: (2016)

Loss of heterozygosity at 7p in Wilms' tumour development
por: Powlesland, R M, et al.
Publicado: (2000)

Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan
por: Sheu, J-C, et al.
Publicado: (1999)

Loss of constitutional heterozygosity on chromosomes 5 and 17 in cholangiocarcinoma.
por: Ding, S. F., et al.
Publicado: (1993)

Loss of heterozygosity on chromosomes 1 and 11 in carcinoma of the pancreas.
por: Ding, S. F., et al.
Publicado: (1992)

Loss of heterozygosity of the oestrogen receptor gene in breast cancer.
por: Iwase, H., et al.
Publicado: (1995)

Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour.
por: Grundy, R. G., et al.
Publicado: (1998)

Genomic loss of heterozygosity and survival in the REAL3 trial
por: Smyth, Elizabeth C., et al.
Publicado: (2018)

Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma
por: Bustamante, Bethany, et al.
Publicado: (2021)

Value of the loss of heterozygosity to BRCA1 variant classification
por: Santana dos Santos, Elizabeth, et al.
Publicado: (2022)

Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein
por: Schwarzenbach, Heidi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_64trush2oar53e7h4fuht7jt2r